Callio Therapeutics
Callio Therapeutics develops dual-payload antibody-drug conjugates (ADCs) for people with cancer, including patients with tumors that have developed resistance to existing therapies. Its platform pairs synergistic drug payloads and uses a proprietary linker to design targeted treatments intended to overcome resistance and deliver more durable responses.
Facts
- HQ
- Seattle, WA, USA
- Sectors
- Biotechnology Research
- Founded
- 2025
- Employees
- 24
- Stage
- Series A
Is this your organization? Claim it
Founders
-
Jerome Boyd-Kirkup Co-Founder
-
Piers Ingram Co-Founder
Executives
-
Chris Hassig Executive, Chief Scientific Officer
-
Kevin Hambly Executive, Chief Business Officer
-
Kiran Asarpota Executive, Chief Operating Officer
-
Meredith Wesley Executive, Chief Human Resources Officer
-
Naomi Hunder Executive, Chief Medical Officer
-
Zachary Hornby Executive, Chief Executive Officer